Phase 3 randomized, open-label study will evaluate MEK 162 vs physician choice of selected chemotherapies in patients with low-grade serous carcinoma of the ovaries, fallopian tubes or primary peritneal who have recurrent or persistent disease following:
- at least 1 prior platinum-based chemotherapy
- no more than 3 prior lines of chemotherapy
- Central pathology review of patient histology tumor specimen
